Active and passive immunotherapy for neurodegenerative disorders - Test2 - elhamkhani - TriplyDB

Active and passive immunotherapy for neurodegenerative disorders

Active and passive immunotherapy for neurodegenerative disorders

http://www.wikidata.org/entity/Q24657879

about

AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease.Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer Disease Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy White matter changes in dementia: role of impaired drainage of interstitial fluid.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Beneficial catalytic immunity to abeta peptide.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distribution Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice Amyloid-beta immunotherapy for Alzheimer's disease CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance Prion protein-specific antibodies-development, modes of action and therapeutics application Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging Current and future treatments for Alzheimer's disease Passive (amyloid-β) immunotherapy attenuates monoaminergic axonal degeneration in the AβPPswe/PS1dE9 mice.Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease.Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice Alzheimer's disease: pathological mechanisms and recent insights.The many faces of tau Could immunomodulation be used to prevent prion diseases?

P2860

Q27318148-BFF64F7A-3E0C-4454-B4A4-3AB0E638EB1E Q27349010-E1F94DAE-AC79-49D4-A5E0-4C8BF3571CF9 Q27658233-A50BA6D7-62FE-447A-B4E4-B2346C20CD84 Q28475740-BD60BEF2-534E-4014-9FC1-210AB225ACF6 Q28740910-A9EF4CBB-CA1B-4831-B272-E249EE4C06FF Q30486176-DC81FC83-F4D2-490F-A50C-D9517F099FE8 Q30493543-CC83A058-3B58-4929-B27D-979F55E40068 Q30497751-53254190-5EDC-4810-AA3C-D95787E38493 Q30499456-6B54C9A0-CF1B-4ABB-B206-9D2047818EF1 Q30880445-FC8E2CB7-6B2B-4149-9ED1-CC6F18DBAFFF Q33392254-C881AA76-BDE8-4436-AB83-5320BD7DE45A Q33549900-70B390B7-7208-4E56-ADE6-14952661B0A1 Q33572338-CDEB51AD-160A-48A7-B6C9-94E8518B7105 Q33573668-945216CE-16A7-455A-8ADE-1EDF6C76DD7D Q33639513-D28E9AF5-DD55-4E73-8728-7348193899EB Q33742312-CE8C4C21-FC1E-4D7B-A070-FC11DAB507C2 Q33831036-41AFFB2F-6745-42BA-B1DF-4BB113A2C73A Q33863420-5BF519F5-D5FE-4BD6-9C30-E9BF9949AA37 Q33926242-80027B8A-21F1-48DC-A65F-F74919A20F5F Q33954737-1D4EFA86-D847-443B-A8EA-7D90775EE537 Q34017180-D8711F77-F5E4-43D2-9615-DDB3186EDF39 Q34043432-81EF73B4-6BF1-49CC-B38F-A44AD0BABBA1 Q34091134-D248937A-D5AF-48B7-83FA-763BF16F5951 Q34348316-C173725A-92D6-4E3E-A1E4-562457A3CE8F Q34383525-DCB34462-D7A6-40E0-96CE-C22A47FF2D40 Q34423386-38FA25B7-325B-46A3-83BF-D404D7F0BA51 Q34543713-AB9EB857-6A9E-47E5-860F-069392660138 Q34548700-E939FA42-A173-4E3C-A479-B2D41D7877B9 Q34611770-BE333482-04F9-4565-BE8D-C8A8CCB7611B Q34646921-28625209-9B3C-4DA8-A8B0-04AD33743450 Q34717836-528BB94B-4DA7-4F75-8B76-78E4D4D1D695 Q34943311-3AE0ADD3-A0B9-40A0-A337-63E6516C4520 Q34960461-902B21E3-EF5B-4091-B558-FF34FB9F2B36 Q35050837-28952563-42CE-40E2-8C93-3407411631C5 Q35137114-F980F948-3894-41E2-970E-53013A36B096 Q35216140-251A4FC7-0CC9-4994-AA1E-5E863B9D3C38 Q35300928-8CB57618-E04F-4982-B707-AA0E076361B3 Q35687044-968A8DE4-DDDA-4949-9F0E-7BD9E6640116 Q35870359-A3B96BF2-42A2-43C4-8DE2-664AC98A1308 Q35875915-5FD395DC-DEC4-4A66-B792-6A54E543DBF9

P2860

Active and passive immunotherapy for neurodegenerative disorders

http://www.wikidata.org/entity/Q24657879

description

2008 nî lūn-bûn

@nan

2008 թուականին հրատարակուած գիտական յօդուած

@hyw

2008 թվականին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Active and passive immunotherapy for neurodegenerative disorders

@ast

Active and passive immunotherapy for neurodegenerative disorders

@en

Active and passive immunotherapy for neurodegenerative disorders

@nl

type

label

Active and passive immunotherapy for neurodegenerative disorders

@ast

Active and passive immunotherapy for neurodegenerative disorders

@en

Active and passive immunotherapy for neurodegenerative disorders

@nl

prefLabel

Active and passive immunotherapy for neurodegenerative disorders

@ast

Active and passive immunotherapy for neurodegenerative disorders

@en

Active and passive immunotherapy for neurodegenerative disorders

@nl

P1433

Q24657879-26755D9E-FF60-4F87-A33C-8C2963594BEC

P1476

Q24657879-381FD396-593A-4EAD-9765-C9B9B037CCCC

P2093

Q24657879-F5348A1C-5C6B-4341-843C-F0B938FE36F0

P2860

Q24657879-081514BB-1956-4AE1-8A1B-94A315997027

Q24657879-088168F2-AA43-472E-BC9B-E0626F1A49D0

Q24657879-0D9C4A5F-E81E-4B28-8C82-3119879103EF

Q24657879-0DCB5EC6-E894-430B-82EC-B9C26A9EC019

Q24657879-0F3FE49A-7543-4890-A5D5-452DAF06074B

Q24657879-0FE05FC2-C872-4A57-8954-71EC1323C098

Q24657879-16856AA5-341D-4D7F-8BA9-8C1BC52A074D

Q24657879-1BFCF2FB-11A0-48C7-A21A-005CAA14D0CA

Q24657879-1E9DBEBF-9C2F-4E7A-88A7-3840F286D134

Q24657879-204C9ABA-5C72-441A-B405-3A2C37717F01

P304

Q24657879-50B85548-0CC5-49BA-AD51-4D487A14C5DA

P31

Q24657879-7BF63DE1-A4A4-4C94-B924-E9DA2CAB48C1

P3181

Q24657879-332FA03C-83B9-4FA5-9B24-5130D5EF9443

P356

Q24657879-821FB133-3876-4224-B649-171340A46950

P407

Q24657879-B7BB8E75-9568-4311-BD13-FCEB64606FB4

P433

Q24657879-2B6DB357-43B3-4405-80DE-A413A28CD6C3

P478

Q24657879-935D2324-FD28-4A10-B898-4FD82B2B4B65

P50

Q24657879-871FC6AC-D7E1-4D46-B9F7-374E4CDF2310

P577

Q24657879-DF28D973-83BA-4F6B-8F78-260A1CFE6107

P5875

Q24657879-1BBE1E09-2A85-4D94-9CEA-E2ECAE8C98FE

P698

Q24657879-CC199F85-E0E6-4F1E-885E-35BF934B0D2C

P921

Q24657879-544105A7-CD66-49D6-8376-480083D40605

Q24657879-C9749747-EE06-4846-941D-EB3D498A14BC

P932

Q24657879-7000FCDD-AFDE-4432-A197-14678440F250

P3181

P356

ANNUREV.NEURO.31.060407.125529

P1433

Annual Review of Neuroscience

P1476

Active and passive immunotherapy for neurodegenerative disorders

@en

P2093

David L Brody

http://www.w3.org/2001/XMLSchema#string

P2860

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease

Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Reversible memory loss in a mouse transgenic model of Alzheimer's disease

A specific amyloid-beta protein assembly in the brain impairs memory

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

P304

175-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5001755

http://www.w3.org/2001/XMLSchema#string

P356

10.1146/ANNUREV.NEURO.31.060407.125529

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5499279

http://www.w3.org/2001/XMLSchema#string

P698

18352830

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

2561172

http://www.w3.org/2001/XMLSchema#string